Investor profile
Sofinnova Partners
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Sofinnova Partners focuses on breakthrough innovations that have the potential to solve the world's most pressing problems in healthcare and sustainability. Founded in 1972 and managing over €4 billion in assets, the firm operates seven complementary investment strategies spanning the full life sciences value chain — from seed-stage company creation (via its MD Start and Biovelocita accelerators) to early-stage biopharma and medtech (Capital Strategy), growth-stage crossover investing (Crossover Strategy), industrial biotech and sustainability (Industrial Biotech Strategy), digital medicine and techbio (Digital Medicine Strategy), and Italian science (Telethon Strategy). The firm describes itself as a hands-on company builder and lead investor, sitting on portfolio company boards and partnering with entrepreneurs who strive to transform biopharma, medtech, digital medicine, agriculture, and industrial processes with cutting-edge science.
Notable quotes
“If you treat patients, you save lives, ultimately this is going to be good for investors. We believe that by backing companies, whether early stage or later stage, that bring a product to patients — ultimately this translates into financial return.”
“We are known for being company creators. We continue to do what we know. Our strategy has evolved, but has remained consistent.”
“All seven of Sofinnova's investment strategies—from incubation to later-stage growth, spanning biotech, medtech, industrial biotech and digital medicine—have capital to back the next generation of life sciences companies. With the new funds, we anticipate supporting 50 to 60 new companies, empowering a new wave of entrepreneurs tackling some of the world's most pressing health and sustainability challenges.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| HAYA Therapeutics | Series A | $65m | 2025-05-08 |
| Purespring Therapeutics | Series B | $105m | 2024-10-09 |
| Novameat | Series A | $19m | 2024-09-12 |
| TISSIUM | Series C | $66m | 2024-06-24 |
| LimFlow | Acquisition (exit) | $250m | 2023-11-01 |
| Moon Surgical | Series B | — | — |
| CorWave | Series B | — | — |
| Mainstay Medical | Growth | — | — |
| Quince Therapeutics | Series A | — | — |
| Signadori Bio | Seed | — | 2025-04-08 |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| Forbion | 5 |
| Gilde Healthcare | 3 |
| Syncona | 2 |
| Earlybird Venture Capital | 2 |
| Bpifrance | 2 |
| OrbiMed | 2 |
Fit check
Is Sofinnova Partners a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit